Mechanistic description
LRRK2 inhibition to restore MiT-TFE-mediated lysosomal function in microglia
Debate provenance: derived from debate sess_SDA-2026-04-03-gap-immune-atlas-neuroinflam-20260402 on question: Comprehensive analysis of immune cell subtypes in neurodegeneration: microglia subtypes (DAM, homeostatic, inflammatory), astrocyte reactivity states, T-cell infiltration. Anchor to existing TREM2 (h-b234254c, h-044ee057) and complement cascade hypotheses (h-58e4635a, h-1fe4ba9b, h-5a55aabc). Produc. Consensus signal: domain_expert, skeptic, synthesizer, theorist discussed the mechanism terms Enhancement, LRRK2, Lysosomal, MiT-TFE, TFE, TFE/LRRK2, inhibition, lysosomal. Novelty signal: skeptic-discussed-with-qualified-concession.
Evidence for (1)
Evidence matrix
Cite this hypothesis
Cite this hypothesis
etl-backfill (2026). MiT-TFE/LRRK2 Lysosomal Enhancement Therapy. SciDEX hypothesis. https://prism.scidex.ai/hypotheses/h-debate-d2fcc1060671
@misc{scidex_hypothesis_hdebated,
title = {MiT-TFE/LRRK2 Lysosomal Enhancement Therapy},
author = {etl-backfill},
year = {2026},
howpublished = {SciDEX hypothesis},
url = {https://prism.scidex.ai/hypotheses/h-debate-d2fcc1060671},
note = {SciDEX artifact hypothesis:h-debate-d2fcc1060671}
}